ArticlePerspectives in medicinal chemistry2014
Multiple sclerosis: overview of disease-modifying agents.
Article in Perspectives in medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.Journal of neurology · 2024Pooled it
- A pilot study to improve adherence among MS patients who discontinue treatment against medical advice.Journal of behavioral medicine · 2016Trial
- Clinical, demographic, and pharmacological predictors of medication adherence to disease-modifying therapies in multiple sclerosis: a multidimensional analysis of merged survey and claims data.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- S3I-201, a STAT3 Inhibitor, Inhibits Proinflammatory Mediator Signalling in CD19 and CD45R/B220 Cells in a Mouse Model of Multiple Sclerosis.Cellular and molecular neurobiology · 2026Article
- Stem cell-derived extracellular vesicles as immunomodulatory agents: targeting pathological crosstalk in systemic lupus erythematosus and multiple sclerosis.Frontiers in medicine · 2026Review
- Decoding the Potential Impact of Plasma hsa-miR-24-3p and hsa-miR-181 d-3p Expression, Plasma IFN-γ Levels, and IFNG rs2069727 T/C Genetic Variant on Multiple Sclerosis Risk and Glatiramer Acetate Treatment.Molecular neurobiology · 2025Article
- Immunogenicity of three-dose COVID-19 vaccines in people living with multiple sclerosis.BMJ neurology open · 2025Article
- Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses.Frontiers in immunology · 2025Observational
- Comparative transcriptome profiling of the lumbosacral dorsal root ganglia reveals sexually dimorphic gene expression in a murine model of coronavirus-induced neurodegeneration.American journal of clinical and experimental urology · 2025Article
- Review
- Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations.Lupus science & medicine · 2024Review
- Short and Medium Chain Fatty Acids in a Cohort of Naïve Multiple Sclerosis Patients: Pre- and Post-Interferon Beta Treatment Assessment.Biologics : targets & therapy · 2024Article
- Comparative effectiveness and safety of ozanimodTherapeutic advances in neurological disorders · 2024Article
- Pyroptosis the Emerging Link Between Gut Microbiota and Multiple Sclerosis.Drug design, development and therapy · 2024Review
- Varicella-zoster virus vasculopathy in a patient with multiple sclerosis receiving natalizumab.BMJ case reports · 2023Article
- Histamine H4 Receptor Antagonist Ameliorates the Progression of Experimental Autoimmune Encephalomyelitis via Regulation of T-Cell Imbalance.International journal of molecular sciences · 2023Article
- Handling related publications reporting real-world evidence in network meta-analysis: a case study in multiple sclerosis.Journal of comparative effectiveness research · 2023Article
- Medication self-management toolkits for adults with multiple sclerosis: A scoping review.Exploratory research in clinical and social pharmacy · 2023Article
- Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria.Lupus science & medicine · 2022Review
- The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis.Clinical epidemiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease that usually affects young adults, causing progressive physical and cognitive disability. Since the 1990s, its treatment has been based on parenteral medications known collectively as immunomodulators. This drug class is considered safe and usually prevents 30% of MS relapses. Drugs in this class exert almost the same efficacy and require an inconvenient administration route. New medications have recently been launched worldwide. Thus, new oral drugs are increasingly being administered to MS patients and contributing to a better quality of life, since these have better efficacy than the old immunomodulators. Today, 10 different drugs for MS are marketed worldwide, which requires deep knowledge among neurologists and other healthcare professionals. This paper summarizes all the drugs approved for MS in the US and Europe, emphasizing their mechanism of action, the results from phase II and III studies, and the product safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.